Drug Profile
PASylated somatropin - XL-protein GmbH
Alternative Names: PAS-hGH; xl-020Latest Information Update: 28 Aug 2018
Price :
$50
*
At a glance
- Originator XL-protein GmbH
- Class Growth hormones; Hormonal replacements
- Mechanism of Action Human growth hormone replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Somatotropin deficiency
Highest Development Phases
- No development reported Somatotropin deficiency
Most Recent Events
- 28 Aug 2018 No recent reports of development identified for preclinical development in Somatotropin-deficiency in Germany
- 09 Aug 2016 Preclinical development is ongoing in Germany
- 09 Aug 2016 PASylated somatropin - XL-protein GmbH is available for licensing as of 09 Aug 2016. http://www.xl-protein.com/